Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Authors
Keywords
-
Journal
Biomed Research International
Volume 2015, Issue -, Pages 1-21
Publisher
Hindawi Limited
Online
2015-06-08
DOI
10.1155/2015/413076
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dose-dense Paclitaxel in Advanced Ovarian Cancer
- (2015) A. Kumar et al. CLINICAL ONCOLOGY
- Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review
- (2014) Vincent A. de Weger et al. ANTI-CANCER DRUGS
- Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer
- (2014) M.E.L. van der Burg et al. EUROPEAN JOURNAL OF CANCER
- Harnessing the immune system for the treatment of breast cancer
- (2014) Xinguo Jiang Journal of Zhejiang University-SCIENCE B
- Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
- (2014) Sandro Pignata et al. LANCET ONCOLOGY
- Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer
- (2014) Xiaoqian Yang et al. PHARMACEUTICAL RESEARCH
- Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016)
- (2013) K. Harano et al. ANNALS OF ONCOLOGY
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Taxanes: Old drugs, new oral formulations
- (2013) Rajni A. Jibodh et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer
- (2013) Keiichi Fujiwara et al. EXPERT OPINION ON PHARMACOTHERAPY
- ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas
- (2013) Sharon E. Johnatty et al. GYNECOLOGIC ONCOLOGY
- Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma — a retrospective study
- (2013) Tamar Safra et al. GYNECOLOGIC ONCOLOGY
- nab-Paclitaxel mechanisms of action and delivery
- (2013) Denise A. Yardley JOURNAL OF CONTROLLED RELEASE
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
- (2013) Noriyuki Katsumata et al. LANCET ONCOLOGY
- TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro
- (2013) AN-CONG WANG et al. Oncology Letters
- Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells
- (2012) Anna Fialová et al. INTERNATIONAL JOURNAL OF CANCER
- Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice
- (2012) Alexandra Sevko et al. Journal of Immunotoxicology
- Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner
- (2012) Tillmann Michels et al. Journal of Immunotoxicology
- Update on taxane development: new analogs and new formulations
- (2012) Katherine Tkaczuk et al. Drug Design Development and Therapy
- Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer
- (2011) Masashi Ando et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment
- (2011) N. Obermajer et al. CANCER RESEARCH
- Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways
- (2011) Nadine Rohwer et al. DRUG RESISTANCE UPDATES
- A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
- (2011) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Regulatory T cells and Foxp3
- (2011) Alexander Y. Rudensky IMMUNOLOGICAL REVIEWS
- Treatment-Related Protein Biomarker Expression Differs between Primary and Recurrent Ovarian Carcinomas
- (2011) D. A. Zajchowski et al. MOLECULAR CANCER THERAPEUTICS
- CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4
- (2011) Y. Zhu et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
- (2011) Cheryl A Sherman-Baust et al. Journal of Ovarian Research
- Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma
- (2010) A. Y. Bedikian et al. ANNALS OF ONCOLOGY
- A phase 2 pilot trial of low-dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma
- (2010) Rupal S. Bhatt et al. CANCER
- Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
- (2010) Lukas W. Pfannenstiel et al. CELLULAR IMMUNOLOGY
- Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress
- (2010) Tanja Hadzic et al. FREE RADICAL BIOLOGY AND MEDICINE
- Selective Impairment of CD4+CD25+Foxp3+Regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis
- (2010) Nan Liu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Regulatory T cells in tumor immunity
- (2010) Hiroyoshi Nishikawa et al. INTERNATIONAL JOURNAL OF CANCER
- Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy
- (2010) Angiolo Gadducci et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Paclitaxel-Dependent Cell Lines Reveal a Novel Drug Activity
- (2010) A. Ganguly et al. MOLECULAR CANCER THERAPEUTICS
- Intraperitoneal Paclitaxel as Consolidation Treatment in Ovarian Cancer Patients: A Case Control Study
- (2010) Pierluigi Benedetti Panici et al. ONCOLOGY
- Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants
- (2010) Peter H. OʼDonnell et al. Pharmacogenetics and Genomics
- The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
- (2009) Xia Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77
- (2009) C. Ferlini et al. CANCER RESEARCH
- Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
- (2009) B. B. Aggarwal et al. CLINICAL CANCER RESEARCH
- Paclitaxel and immune system
- (2009) Aqeel Javeed et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
- (2009) Michael G. Teneriello et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
- (2009) Ramon Kaneno et al. Journal of Translational Medicine
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
- (2008) Monica Mita et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies
- (2008) Paula M. Fracasso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse
- (2008) Alain P. Vicari et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Regulatory T Cells and Immune Tolerance
- (2008) Shimon Sakaguchi et al. CELL
- Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy
- (2008) Lei Zhang et al. CLINICAL IMMUNOLOGY
- A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer
- (2008) Sandro Pignata et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study
- (2008) Paul Sabbatini et al. GYNECOLOGIC ONCOLOGY
- TLR signaling by tumor and immune cells: a double-edged sword
- (2008) B Huang et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now